ScreenerHero

CVKDCadrenal Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · cadrenal.com
1.610USD-1.83%Mkt Cap: 4.99M $P/E: —

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.99M $
Enterprise Value3.28M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.24M $
Revenue/Share—
Last Price1.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.47
PEG—
EV/EBITDA-0.28
EV/Revenue—
P/S—
P/B1.20
EPS (TTM)-4.79
EPS (Forward)-3.40
52W Range
1.5411% of range14.64
52W High14.64 USD
52W Low1.541 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-483.34%
ROA-305.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.60M $
CapEx (TTM)5.10K $
FCF Margin—
FCF Yield-166.79%
Net Debt-2.39M $
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity—
Current Ratio3.73
Quick Ratio3.39
Book Value/Sh1.321 USD
Cash/Share0.6690 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 20, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.00 USD
Upside (mean)+769.6%
Target Range12.00 USD – 17.00 USD
$12.00+769.6% to mean$17.00
# Analysts3
Ownership
Shares Out.3.10M
Float3.04M
Insiders11.93%
Institutions9.79%
Short Interest
Short Ratio0.7d
Short % Float1.97%
Short % Out.1.71%
Shares Short61.10K
Short (prev mo.)82.02K
Technical
SMA 502.536 (-36.5%)
SMA 2006.065 (-73.5%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)54.12K
Avg Vol (10d)46.04K
Technical Indicators
RSI (14)25.9
MACD-0.2660
MACD Signal-0.2906
MACD Hist.+0.0245
BB Upper2.184 USD
BB Middle1.922 USD
BB Lower1.660 USD
BB Width27.25%
ATR (14)0.2096 USD
Vol Ratio (20d)0.91x